Quantcast

Latest Heart failure Stories

2014-05-16 23:00:57

American Heart Association Awards Mount Sinai Beth Israel Heart Failure Program a Get With The Guidelines®–Heart Failure Gold Quality Achievement Award New York, NY (PRWEB) May 16, 2014 Mount Sinai Beth Israel is the proud recipient of the 2014 American Heart Association’s Get With The Guidelines®–Heart Failure Gold Quality Achievement Award. It is one of only three hospitals in New York City to have earned the prestigious designation. The Gold level award recognizes...

2014-05-15 16:28:57

Takeda Emphasizes Continued Commitment to ACTOS and Patient Safety DEERFIELD, Ill., May 15, 2014 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. announced today that in the case of Whitlatch v. Takeda the jury found in favor of Takeda. The trial began on April 21 in the Circuit Court of Cook County, Illinois, before Judge Deborah Dooling and is the fifth ACTOS (pioglitazone HCl) case to reach trial. "We empathize with the Whitlatch family but agree with the verdict," said...

2014-05-15 08:33:06

Completes Enrollment in Phase 2b Clinical Trial of CLP-1001 for Heart Failure SUNNYVALE, Calif., May 15, 2014 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced the closing a $6.5 million tranche in a $15 million Series D financing. Existing investors CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds participated in the round. Sorbent also...

2014-05-13 23:01:45

Mount Sinai study reports the socioeconomic status of congestive heart failure patients does not influence hospital rankings for heart failure readmissions. New York, NY (PRWEB) May 13, 2014 A new report by Icahn School of Medicine at Mount Sinai, published in the journal Circulation: Cardiovascular Quality and Outcomes, shows the socioeconomic status of congestive heart failure patients does not influence hospital rankings for heart failure readmissions. In the study, researchers...

2014-05-13 15:39:04

The Hebrew University of Jerusalem Hebrew University Faculty of Medicine researchers show for the first time that the protein Erbin is an important brake that helps prevent pathological cardiac hypertrophy Research also has implications for the treatment of breast cancer Cardiovascular disease remains the number one cause of death in the Western world, with heart failure representing the fastest-growing subclass over the past decade.  The stage that precedes heart failure in a...

2014-05-09 16:24:25

At Heart Rhythm 2014, panel of experts from three prominent medical groups share recommendations for patient populations not well represented in current guidelines SAN FRANCISCO, May 9, 2014 /PRNewswire/ -- The Heart Rhythm Society (HRS), American College of Cardiology (ACC) and American Heart Association (AHA) released Expert Consensus Statement on the Use of Implantable Cardioverter Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials...

2014-05-09 08:26:52

FRAMINGHAM, Mass., May 9, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference at 12:00 p.m. PDT (3:00 p.m. EDT) on Tuesday, May 13, 2014. The conference is being held May 12-15 at the Encore at...

2014-05-08 08:34:00

In Reddit's 'Ask Me Anything' Section, Randy Shepherd Responds to Hundreds of Questions about His 10-Plus Months with the SynCardia Total Artificial Heart & His Completion of the 4.2-Mile Pat's Run on April 26, 2014 TUCSON, Ariz., May 8, 2014 /PRNewswire/ -- Randy Shepherd's fascinating story of life with a SynCardia temporary Total Artificial Heart has touched the hearts of many who have found inspiration as well as information on how the world's first and only FDA, Health Canada...

2014-05-06 08:36:03

CLEVELAND, May 6, 2014 /PRNewswire-USNewswire/ -- Juventas Therapeutics today announced that top-line interim data from its ongoing Phase II STOP-HF study will be presented in a late-breaking oral presentation at the European Society of Cardiology Heart Failure Congress (ESC-HF) taking place May 17 - 20, 2014 in Athens, Greece. The STOP-HF trial is a randomized, placebo-controlled, double-blinded study conducted at 15 centers in the United States to evaluate safety and efficacy of...

2014-05-05 08:29:16

Six-month Outcomes of AUGMENT-HF Multicenter Study to Be Presented by Yearend LAGUNA HILLS, Calif., May 5, 2014 /PRNewswire/ -- LoneStar Heart, Inc. today announced that it completed the patient recruitment phase of the company's AUGMENT-HF controlled randomized trial of Algisyl-LVR hydrogel implant, its lead product for the treatment of advanced heart failure (HF). LoneStar Heart expects to present six-month outcomes by yearend. The AUGMENT-HF clinical trial is being conducted at...


Latest Heart failure Reference Libraries

Circulation (journal)
2012-06-04 14:21:01

Circulation is a scientific journal published by Lippincott Williams & Wilkins on behalf of the American Heart Association. In 2008 the journal added six subspecialty publications: Circulation: Arrhythmia and Electrophysiology, Circulation: Heart Failure, Circulation: Cardiovascular Imaging, Circulation: Cardiovascular Interventions, Circulation: Cardiovascular Quality and Outcomes, and Circulation: Cardiovascular Genetics. Circulation publishes articles related to research in and the...

More Articles (1 articles) »
Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related